<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04505904</url>
  </required_header>
  <id_info>
    <org_study_id>CGOT1620</org_study_id>
    <nct_id>NCT04505904</nct_id>
  </id_info>
  <brief_title>Oxytocin and Approach-avoid in Grief</brief_title>
  <official_title>A Pull to be Close: the Differentiating Effects of Oxytocin and Grief Stimulus Type on Approach Behavior in Complicated Grief</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <brief_summary>
    <textblock>
      This is a completed project which was initiated prior to January 18,2017&#xD;
&#xD;
      Background: Theoretical models of complicated grief (CG) suggest that maladaptive approach&#xD;
      (e.g., perseverative proximity-seeking of the deceased) or avoidance (e.g., excessive&#xD;
      avoidance of reminders) behaviors interfere with a person's ability to integrate the loss and&#xD;
      recover from their loved one's death. Due in part to conflicting evidence, little mechanistic&#xD;
      understanding of how these behaviors develop in grief exists. We sought to (1) identify&#xD;
      behavioral differences between CG and non-CG groups based on implicit bias for grief-,&#xD;
      deceased-, and social-related stimuli, and (2) test the role of the neuropeptide oxytocin in&#xD;
      shaping approach/avoidance bias.&#xD;
&#xD;
      Methods: Widowed older adults with (n = 17) and without (n = 22) CG completed an&#xD;
      approach/avoidance task measuring implicit bias for personalized, non-specific,&#xD;
      grief-related, and other stimuli. In a double-blinded, randomized, counterbalanced design,&#xD;
      each participant attended both an intranasal oxytocin session and a placebo session. Aims&#xD;
      were to (1) identify differential effects of CG and stimulus type on implicit&#xD;
      approach/avoidance bias [placebo session], and (2) investigate interactive effects of CG,&#xD;
      stimulus type, and oxytocin vs. placebo on approach/avoidance bias [both sessions].&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2015</start_date>
  <completion_date type="Actual">May 12, 2017</completion_date>
  <primary_completion_date type="Actual">May 12, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Reaction Time</measure>
    <time_frame>120 minutes</time_frame>
    <description>Participant reaction time to visual stimuli in a behavioral task</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Prolonged Grief Disorder</condition>
  <condition>Bereavement</condition>
  <arm_group>
    <arm_group_label>Syntocinon First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received syntocinon at visit one and placebo at visit two. Syntocinon is 24 IU dose administered intranasally in spray form.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo First</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Crossover design, all participants received experimental condition at either visit one or visit two, and the placebo at the other visit. This arm designates those who received placebo at visit one, and syntocinon at visit two.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Syntocinon</intervention_name>
    <description>Synthetic oxytocin spray, 24 IU per spray.</description>
    <arm_group_label>Placebo First</arm_group_label>
    <arm_group_label>Syntocinon First</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo spray with no active ingredient.</description>
    <arm_group_label>Placebo First</arm_group_label>
    <arm_group_label>Syntocinon First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Adult individual experiencing death of a spouse or partner between 6 and 36 months prior&#xD;
        to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to comprehend English;&#xD;
&#xD;
          -  medical contraindications for other components of the study,&#xD;
&#xD;
          -  active suicidality&#xD;
&#xD;
          -  active homicidality&#xD;
&#xD;
          -  active psychotic symptoms&#xD;
&#xD;
          -  ongoing major health conditions such as cancer; uncontrolled hypertension; and&#xD;
             medications likely to impact the oxytocin system (e.g., systemic corticosteroids).&#xD;
&#xD;
          -  pregnant status or suspected pregnant status&#xD;
&#xD;
          -  premenopausal status&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxytocin</keyword>
  <keyword>Approach/Avoid</keyword>
  <keyword>Older adults</keyword>
  <keyword>Complicated Grief</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 27, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT04505904/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>July 9, 2021</submitted>
    <returned>July 30, 2021</returned>
    <submitted>October 25, 2021</submitted>
    <returned>November 16, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

